Method of producing nutritional products from human milk tissue and compositions thereof

a technology of human milk tissue and nutritional products, applied in the field of biopharmaceutical and nutritional products obtained, can solve the problems of affecting the scientific investigation of human milk, unable to standardized source human milk, and unable to meet the needs of human milk research, and achieve the effect of highly targeted use and reducing the ill effects of upcoming procedures

Inactive Publication Date: 2005-05-12
PROLACTA BIOSCI
View PDF6 Cites 37 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] The sequential administration of many of the human milk constituents provides substantial value to the recipient because of metabolic and catabolic processes. It is at the core of the present invention to utilize such human milk constituents, in their processed form, in such a sequential fashion as to provoke the same type of chain reaction in the body. With this concept, the pairing of the processed milk tissue with the sequential and differentiated delivery methods, patients may enjoy a new type of preventative and therapeutic medicine. Because human milk immunoglobulins are specifically targeted to many diseases of the newborn, as well as the protective functions of the mucus membranes of the newborn's body, and contain higher levels of IgA, IgD, IgM and IgE...

Problems solved by technology

The lack of a standardized source of human milk, available for research purposes, has seriously hampered scientific investigation of human milk as well as the majority of the nearly 4,000 unique, species-specific milks.
Although the presence of immunoglobulins in human milk has been acknowledged for a number of years, the specific role and function of each of the human milk immunoglobulins and their subclasses has been poorly understood.
For the patient of any age suffering from an immune disorder, the worldwide gamma globulin shortage is impacting care to such a degree that some patients are unable to obtain treatment.
Until recently, the reasons behind the superiorit...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Gamma Globulin Formulations

[0023] At the center of this invention, is the intent to solve the worldwide shortage of gamma globulin. The current source of gamma globulin is blood serum, and specifically IgG from human blood. The present invention discloses a prophetic inclination, based upon a 15-year study of human milk, that a new form of gammaglobulin referred to herein as “panaglobulin,”“mammaglobulin” or “lactopanaglobulin” may replace the current gamma globulin. Because higher levels of IgA and IgM are present in human milk and colostrums, and a more diverse form of IgG as well, panaglobulins may provide protection beyond the scope of current gamma globulin therapy. Manipulation of the levels of immunoglobulins and their subclasses will result in formulations that are targeted at specific diseases or organ systems, making it possible to attack disease using nature's pharmaceutical laboratory, the mammary gland. Furthermore, milk donors who have weaned their babies or have init...

example 2

Collection of Donor Milk

[0027] U.S. Pat. No. 4,772,262, which is hereby incorporated by reference in its entirety, is directed to technology for milk removal. As disclosed in that patent, milk yields increase due to the sensory stimulus provided by the patented breast pump equipment. When milk yield increases, the formulation of milk including many of the valuable immunoglobulins also increase along with living cells, such as macrophages and lymphocytes. Lipids also increase and the mother's body responds to the stimulus by producing higher levels of prolactin that will trigger continuing milk supply and the secretion of additional nutrients into her milk.

example 3

Storage of Donor Milk

[0028] Previous methods of collecting donor milk failed to recognize the importance of stimulation to the mammary gland as well as collection chambers designed for the anaerobic collection and transfer of donor milk. The invention describes such a method as part of its unique collection, storage and transfer system. Additionally, the preservation of milk components and nutrients is paramount to the success of the invention wherein harvesting of milk cells specific to the species will result in pharmaceutical and nutritional improvements in outcomes for the newly born or immune compromised patient. For that reason, it is important that the container in which the donor milk is stored, will preserve and protect these vital milk constituents from harm due to ultraviolet light and other damaging light rays. A UV coating or additive, applied to the collection bottle during the molding process or afterwards as an exterior coating or sheath will ensure that light degra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods of isolating, treating, storing and processing human milk, as well as nutritional formulations of human milk comprising protective human milk proteins.

Description

[0001] This application claims priority to U.S. Provisional Patent Application Ser. No. 60 / 290,823, filed May 14, 2001.FIELD OF THE INVENTION [0002] The present invention relates to biopharmaceutical and nutritional products obtained from human milk and mammary gland secretions. More particularly, the present invention relates to methods of isolating, storing, transferring, processing, packaging and delivering pharmaceutical and nutritional formulations comprising cells and tissues of human milk, fractionated human milk components and specifically reunited components of human milk. One embodiment of the present invention relates to improving the nutrition of low birth weight infants. Another embodiment of the present invention relates to a novel type of immunoglobulin useful in treating disorders, such as, for example, cancer, immune disorders, gastrointestinal disorders, nutritional disorders and metabolic disorders. BACKGROUND OF THE INVENTION [0003] The lack of a standardized sou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A23C9/20A61K35/20
CPCA61K35/20A23C9/206A61P1/00A61P3/00A61P25/00A61P37/00
Inventor MEDO, ELENA MARIA
Owner PROLACTA BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products